AbbVie strikes deal worth up to $2.54B with Disco Pharmaceuticals for cancer therapies
AbbVie agreed to pay up to $2.54 billion to develop antibody-drug conjugate and T cell engager cancer treatments with Disco Pharmaceuticals, a preclinical German biotech. The deal expands AbbVie's oncology pipeline targeting solid tumors.